Phase III, double-blind, placebo-controlled study of interferon gamma-1b (ACTIMMUNE®) for the treatment of Friedreich’s Ataxia
Ages: 10-25
Location: Children's Hospital of Philadelphia (CHOP), University of Iowa, University of Florida (Gainesville, FL) and UCLA (Los Angeles, CA)
Details: The study is recruiting children and young adults ages 10-25 with Friedreich's Ataxia for a Phase III, double-blind, placebo-controlled clinical trial studying the safety, efficacy, and pharmacokinetics of IFN-γ (interferon gamma-1b, ACTIMMUNE) in FA. This study is funded by Horizon Pharma Ireland, Ltd. and will include approximately 90 patients at four sites in the United States.
For more information, visit the study's clinicaltrials.gov site: www.clinicaltrials.gov/ct2/show/NCT02415127
Please see the study flyers below and contact the study coordinators listed for each site with any questions.
